Susceptibility of Moulds from Two Open, Randomised, Comparative Studies of the Efficacy and Safety of Voriconazole (VORI) Vs Amphotericin B (AMB) in the Treatment of Acute Invasive Aspergillosis (AIA) in Immunocompromised Patients

P. F. TROKE1, A. ESPINEL-INGROFF2, E. M. JOHNSON3, H. SCHLAMM4;

Author address: 

1Pfizer Central Research, Sandwich, Kent, United Kingdom, 2Medical College of Virginia, Chareleston, VA, 3Public Health Laboratory Service, Bristol, United Kingdom, 4Pfizer Inc, New York, NY.

Abstract: 

In total, 381 subjects from The Americas, Europe, Australia and India received study drug (196 VORI and 185 AMB). Entry of definite (culture proven) or probable cases was allowed. All isolates sent to the reference laboratories were re-identified and tested for susceptibility to VORI, itraconazole (ITRA) and AMB using the NCCLS M-38P method. Data are for 210 isolates from 141 subjects; A. fumigatus (99 subjects), A. niger (14), A. flavus (9), A. terreus (9), A. nidulans (5), A. glaucus (1), A. sydowii (1), Zygomycetes (5).&Table;Main sample sources were BAL, sputum, and tissue biopsy. Subjects with sequential isolates (13 VORI & 16 AMB), often had a poorer outcome. None of these isolates showed notable MIC changes over time. There were no susceptibility differences between isolates from the two studies. Most Zygomycetes were unsusceptible to VORI. For 5 isolates (3 A. terreus, 1 A. glaucus, 1 A. flavus), MICs for AMB were 4 mcg/ml. VORI (and ITRA) are more potent against Aspergillus spp in vitro than AMB. The clinical relevance of these data may be shown by comparative studies of VORI Vs AMB in AIA
2001

abstract No: 

NULL

Full conference title: 

ICAAC 41st
    • ICAAC 41st